ID   CHLA-136
AC   CVCL_6590
SY   CHLA_136
DR   Cosmic; 930053
DR   Cosmic; 1890103
DR   IARC_TP53; 23825
DR   Wikidata; Q54812160
RX   PubMed=11212268;
RX   PubMed=11507071;
RX   PubMed=20922763;
RX   PubMed=23202128;
RX   PubMed=24792489;
WW   https://www.cccells.org/PDF_Files/NB_Cell_Lines/CHLA-136%20Cell%20Line%20Data%20Sheet.pdf
WW   http://www.pptpinvitro.org/cell_lines_panel.php
CC   Part of: NCI Pediatric Preclinical Testing Program (PPTP) cell line panel.
CC   Doubling time: 53 hours (PubMed=20922763); 44 hours (COG).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; None_reported; -; Zygosity=- (PubMed=11507071).
ST   Source(s): COG; PubMed=20922763
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 8,11
ST   D16S539: 9,12
ST   D18S51: 12,18
ST   D19S433: 13,14
ST   D21S11: 31.2,32.2
ST   D2S1338: 23,25
ST   D3S1358: 15,18
ST   D5S818: 9,12
ST   D7S820: 8
ST   D8S1179: 10,13
ST   FGA: 23,25
ST   TH01: 7
ST   TPOX: 8,11
ST   vWA: 16,17
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_A054 ! CHLA-122
SX   Female
AG   3Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 18
//
RX   PubMed=11212268;
RA   Thompson P.M., Maris J.M., Hogarty M.D., Seeger R.C., Reynolds C.P.,
RA   Brodeur G.M., White P.S.;
RT   "Homozygous deletion of CDKN2A (p16INK4a/p14ARF) but not within 1p36
RT   or at other tumor suppressor loci in neuroblastoma.";
RL   Cancer Res. 61:679-686(2001).
//
RX   PubMed=11507071;
RA   Keshelava N., Zuo J.J., Chen P., Waidyaratne S.N., Luna M.C.,
RA   Gomer C.J., Triche T.J., Reynolds C.P.;
RT   "Loss of p53 function confers high-level multidrug resistance in
RT   neuroblastoma cell lines.";
RL   Cancer Res. 61:6185-6193(2001).
//
RX   PubMed=20922763; DOI=10.1002/pbc.22801;
RA   Kang M.H., Smith M.A., Morton C.L., Keshelava N., Houghton P.J.,
RA   Reynolds C.P.;
RT   "National Cancer Institute pediatric preclinical testing program:
RT   model description for in vitro cytotoxicity testing.";
RL   Pediatr. Blood Cancer 56:239-249(2011).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//